Analyst Reiterated/Price Target Changed: PHAT rating Buy by Needham
Price Target: $23>>26
Report Date: 01-05-2024
Symbol: PHAT - Phathom Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Analyst Reiterated/Price Target Changed: PHAT rating Buy by Needham
Price Target: $23>>26
Phathom Pharmaceuticals, Inc. (PHAT)
100 CAMPUS DRIVE,, SUITE 102
Florham Park, NEW JERSEY 07932
Phone: 18777428466
Website: http://www.phathompharma.com
CEO: Ms. Terrie J. Curran
NASDAQ, Nasdaq Global Select
Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is based in Buffalo Grove, Illinois.
free stock signal software, free trading signals, free stock trading signals, free trading signals
Good stock signals have been found on this server. That is all we know.
+1 (407) 559-7228